Skip to main content

The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target

Notice

The full text article is available externally.

View from original source.

Evidences have demonstrated key mediatory roles of microRNA-205 (miR-205) in normal physiology and its aberrant expression in many cancers. Indeed, miR-205 has been identified as both a tumour suppressive and oncogenic miRNA playing crucial roles in tumourigenesis through regulating different cellular pathways such as cell survival, apoptosis, angiogenesis and metastasis. As a tumour suppressor, miR-205 acts as an inhibitor of cell proliferation, migration and invasion. On the other hand, as an oncogene, miR-205 promotes tumour initiation and development. All these functions act through different target genes in various types of cancers. Also, miR-205 displays potential as a therapeutic target for different cancers. To conclude, miR-205 has important clinical and pathological correlations in different cancers and may act as a diagnostic and prognostic marker as well as new molecular target for cancer therapy.

Keywords: Carcinoma; cancer; miRNA-205; microRNA; oncogene; tumour suppressor gene

Document Type: Research Article

Publication date: September 1, 2014

More about this publication?
  • Current Cancer Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular drug targets involved in cancer, e.g. disease specific proteins, receptors, enzymes, genes.
    Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in cancer.
    As the discovery, identification, characterization and validation of novel human drug targets for anti-cancer drug discovery continues to grow; this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Call for Papers
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content